Back to Search
MELODY COBLEIGH M.D.
M.D.
Medical Oncology Physician
NPI: 1861451122IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
036-054142(IL)
Education
RUSH MEDICAL COLLEGE OF RUSH UNIVERSITY
Class of 1976
Research & Publications (20)
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
PMID 16361546·Clin Cancer Res·2005
8-other
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
PMID 14613032·Semin Oncol·2003
3-trial
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast.
PMID 19251087·Int J Radiat Oncol Biol Phys·2009
6-review
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
PMID 18496750·Breast Cancer Res Treat·2009
3-trial
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
PMID 18824714·J Clin Oncol·2008
3-trial
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
PMID 18347007·J Clin Oncol·2008
3-trial
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
PMID 18160686·N Engl J Med·2007
3-trial
The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.
PMID 17097880·Breast·2007
8-other
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
PMID 16782917·J Clin Oncol·2006
3-trial
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
PMID 15681523·J Clin Oncol·2005
3-trial
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
PMID 16234499·JAMA·2005
4-observational
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
PMID 15545664·J Clin Oncol·2005
6-review
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
PMID 16137435·Clin Breast Cancer·2005
8-other
Determination of factors associated with hospitalization in breast cancer survivors.
PMID 15547631·Oncol Nurs Forum·2004
8-other
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
PMID 15020607·J Clin Oncol·2004
3-trial
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.
PMID 15041714·Clin Cancer Res·2004
3-trial
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
PMID 12732612·J Clin Oncol·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1725 W HARRISON ST, SUITE 1010
CHICAGO, IL 60612 - Phone
- (312) 942-5904
Quick Facts
- NPI
- 1861451122
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 50
- Publications
- 20
Are you this provider?
Claim Your Profile